Martina Schinke

Martina joins Vedere Bio II with nearly 20 years of experience in program leadership, strategic alliance and program management in academic, pharmaceutical, and biotech settings. Most recently, Martina provided program leadership for development of a novel class of biological drugs at Finch Therapeutics, aiming to restore microbiome functionality in Autism Spectrum Disorder and disorders of the gastrointestinal tract. Previously, Martina provided program management support for bluebird bio’s oncology franchise (now 2seventy bio) and co-led development of bluebird’s lead oncology CAR T cell therapy product ABECMA® from research through clinical development in collaboration with Celgene/BMS. Martina was formerly with the Novartis Institute for Biomedical Research where she held senior project leadership positions over a nearly 10-year tenure and provided strategic and operational leadership for multiple Novartis early discovery and development programs in several therapeutic areas. Prior to her time at Novartis, she was overseeing the microarray facility at the Bauer Center for Genomics Research at Harvard University and was Instructor in Medicine at Harvard Medical School.

Martina holds a PhD from the University in Heidelberg, Germany, and completed her postdoctoral training at the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston.